Sulzer Medica: Nothing New from Sulzer AG

  ZURICH, Switzerland, Dec. 20 /PRNewswire/ -- In a press release published 
this evening, Sulzer AG announced legal steps to be taken against one-time 
subsidiary Sulzer Medica.  This action represents no new development.  
Dr. Stephan Rietiker, CEO of Sulzer Medica, commented on the action of 
Sulzer AG by saying:  "It is our clear intent to quickly and fairly compensate 
any affected patients in the USA.  We will not be deterred from this path by 
third parties. Sulzer AG remains welcome to participate in the settlement."  
Sulzer Medica's subsidiary companies develop, produce, and distribute 
medical implants and biological materials for cardiovascular and orthopedic 
markets worldwide.  The product array includes artificial joint, vertebral, 
and dental implants, trauma products, heart valves, synthetic blood vessels 
and stents for vascular and non-vascular obstructions.  (Swiss Stock Market 
symbol: SMEN, New York Stock Exchange symbol: SM).  
  THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION 
REFORM ACT 1995  
This report contains forward-looking statements including, but not limited 
to, projections of future performance of materials and products, financial 
conditions, results of operations and cash flows, containing risks and 
uncertainties.  These statements are subject to change based on known risks 
detailed from time to time in the Company's Securities and Exchange Commission 
filings and other known and unknown risks and various other factors which 
could cause the actual results or performance to differ materially from the 
statements made herein.  
  This news release is available on the Internet at: 
http://www.sulzermedica.com.  The company's quarterly report is available on 
the Sulzer Medica corporate web site at http://www.sulzermedica.com 
"Investors" / "Financial reports". 
  

SOURCE  Sulzer Medica  
-0-                             12/20/2001  
/CONTACT:  Beatrice Tschanz, +41-1-308-38-66, or fax, +41-1-308-35-06, or 
Andy Bantel, +41-1-308-37-69, or mobile, +41-79-231-56-62, or fax, 
+41-1-308-35-06, or press-relations@sulzermedica.com, both of Sulzer Medica 
Corp. Communications; or Investors, Michael Staheli, +41-1-308-38-64, or fax, 
+41-1-308-35-08, or investor-relations@sulzermedica.com, or U.S., Jim Johnson, 
+1-713-561-6376, or fax, +1-713-561-6380, or 
investor-relations-us@sulzermedica.com, both of Sulzer Medica/  
/Web site:  http://www.sulzermedica.com /  
(SM)  
CO:  Sulzer Medica; Sulzer AG 
ST:  Switzerland 
IN:  HEA MTC 
SU:  LAW  
-0- Dec/20/2001 19:52 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.